# Avance Biosciences: Analytical and Bioanalytical Solutions Empowering Drug Development and Manufacturing > Avance Biosciences is a leading Contract Research Organization \(CRO\) and Contract Testing Organization \(CTO\) providing CGMP and GLP\-compliant analytical Generated by Yoast SEO v28.6, this is an llms.txt file, meant for consumption by LLMs. ## Pages - [Avance Biosciences Contract Research Organization \- About Us](https://www.avancebio.com/about/): Avance Biosciences is a premier CRO and CTO delivering CGMP/GLP\-compliant analytical and bioanalytical services, method development, validation, and testing to accelerate drug development and manufacturing worldwide\.\.\. - [Contact Avance Biosciences](https://www.avancebio.com/contact-us/): Our highly experienced scientists, quality professionals and biotechnology service experts are here to assist you with all your drug development and manufacturing support needs\.\.\. - [Terms of Use](https://www.avancebio.com/about/terms-of-use/) - [Privacy](https://www.avancebio.com/about/privacy/) - [Cell Therapies \- Analytical Testing Services](https://www.avancebio.com/modality/cell-gene-therapy/): Avance Biosciences provides CGMP\- and GLP\-compliant testing services for cell therapies, including CAR\-T and stem cells, delivering analytical and bioanalytical support from development through clinical trials and commercialization\.\.\. - [Gene Therapy \- Analytical Testing Services](https://www.avancebio.com/modality/gene-therapies/): Avance Biosciences provides comprehensive gene therapy analysis services, delivering GLP/CGMP\-compliant analytical and bioanalytical testing for viral vectors, plasmids, and mRNA therapies across development, clinical, and CMC stages\.\.\. - [Preclinical Gene Editing Analysis](https://www.avancebio.com/services-3/preclinical-studies/gene-editing-profiling/): Gene editing analysis evaluates on\- and off\-target stability to ensure safe, effective gene and cell therapies\. Avance Biosciences applies NGS amplicon sequencing, ddPCR, and qPCR to deliver regulatory\-ready preclinical and clinical PK/PD data\.\.\. - [Analytical Services for mAb, ADC, and Protein Drugs](https://www.avancebio.com/modality/biologics/): Avance Biosciences provides comprehensive analytical services for mAbs, ADCs, and protein drugs, delivering genomics, proteomics, and immunoassay support across preclinical, clinical, and CMC stages to ensure safety, quality, and efficacy\.\.\. - [Vaccines \- Analytical Services for Vaccine Development](https://www.avancebio.com/modality/vaccines/): Avance Biosciences delivers comprehensive analytical services for vaccine development, including mRNA vaccines, providing genomics, proteomics, and immunoassay support across preclinical, clinical, and CMC stages to ensure safety, efficacy, and quality\.\.\. - [Small Molecule Drugs \- Bioanalytical Services for Small Molecule Drug Development](https://www.avancebio.com/modality/small-molecule-drugs/): Avance Biosciences provides bioanalytical services for small molecule drugs, using genomics and proteomics to analyze gene and protein expression and support PK/PD, biomarker studies, and regulatory\-ready preclinical and clinical development\.\.\. - [CGMP/GLP\-Compliant Next Generation DNA Sequencing Services](https://www.avancebio.com/tecchnology/next-generation-sequencing-ngs-center-of-excellence/next-gen-sequencing-service/): Next\-generation DNA sequencing enables genomic profiling, biomarker discovery, and characterization across drug and gene therapy development\. Avance Biosciences delivers CGMP/GLP\-compliant NGS using advanced platforms for validated, regulatory\-ready results\.\.\. - [Next\-Generation Sequencing \(NGS\) Center of Excellence](https://www.avancebio.com/tecchnology/next-generation-sequencing-ngs-center-of-excellence/): Avance Biosciences’ NGS Center of Excellence delivers CGMP/GLP\-compliant sequencing across Illumina, PacBio, Nanopore, AVITI, and 10x Genomics to support vector characterization, CRISPR analysis, biodistribution, and other regulatory\-ready biopharmaceutical development\.\.\. - [Potency Assay Development Services for CMC Support](https://www.avancebio.com/services-3/cmc-support/potency-assay-development/): Potency assay services evaluate the biological activity of cell and gene therapies to meet IND and BLA requirements\. Avance Biosciences designs, validates, and runs custom GMP potency assays using advanced bioanalytical technologies\.\.\. - [Analytical Support for mRNA Therapeutics](https://www.avancebio.com/services-3/cmc-support/mrna-ds-dp-testing/): Analytical support for mRNA therapeutics ensures identity, purity, potency, and stability of mRNA vaccines and products\. Avance Biosciences delivers CGMP DS/DP testing, including sequencing, RT\-qPCR, impurity, encapsulation, and sterility assays for release readiness\.\.\. - [DNA Biodistribution Studies for Biopharma Drug Development](https://www.avancebio.com/services-3/preclinical-studies/dna-biodistribution-study/): Biodistribution studies assess the distribution and persistence of gene vectors and therapeutic cells using qPCR and ddPCR to evaluate safety and efficacy\. Avance Biosciences designs and executes GLP and non\-GLP assays with proven workflows for reliable, high\-quality results\.\.\. - [Immunogenicity Testing Services for Biopharma Drug Development](https://www.avancebio.com/services-3/preclinical-studies/ada-studies-immunogenicity-testing-new-style/): Immunogenicity testing evaluates immune responses and anti\-drug antibodies to ensure biologic safety and efficacy\. Avance Biosciences designs multi\-tiered ADA and NAb assays using advanced methods to deliver regulatory\-ready preclinical and clinical data\.\.\. ## Posts - [Case Study: Developing an NGS\- and ddPCR\-Based Potency Assay for a Lipid Nanoparticle \(LNP\) Gene\-Editing Drug Product](https://www.avancebio.com/case-study-developing-an-ngs-and-ddpcr-based-potency-assay-for-a-lipid-nanoparticle-lnp-gene-editing-drug-product/): Avance Biosciences developed and compared NGS and ddPCR\-based potency assay platforms for a client’s LNP gene\-editing drug product, screening candidate cell lines and dose ranges to establish a reproducible, cross\-validated readout method\. - [Case Study: Evaluating On\- and Off\-Target Gene\-Editing Activity of an LNP Drug Product in a Cell\-Based Model](https://www.avancebio.com/case-study-evaluating-on-and-off-target-gene-editing-activity-of-an-lnp-drug-product-in-a-cell-based-model/): Avance Biosciences developed a cell\-based NGS assay to characterize on\- and off\-target gene\-editing activity for a client’s LNP drug product, comparing editing at both loci across single\-dose and repeated low\-dose exposure to support its nonclinical characterization program\. - [Case Study: Validating a Flow Cytometry Identity Assay for cGMP Cell Therapy Drug Substance Release](https://www.avancebio.com/case-study-validating-a-flow-cytometry-identity-assay-for-cgmp-cell-therapy-drug-substance-release/): This case study details how Avance Biosciences validated a multi\-color flow cytometry identity assay for cGMP cell therapy drug substance release, confirming specificity and precision across five surface markers\. The method met predefined acceptance criteria across three analysts and multiple days under a pre\-approved validation protocol\. - [Case Study: Qualifying an LC\-MS/MS Potency Assay for a Lentiviral Gene Therapy Vector](https://www.avancebio.com/case-study-qualifying-an-lc-ms-ms-potency-assay-for-a-lentiviral-gene-therapy-vector/): This case study details how Avance Biosciences qualified an LC\-MS/MS potency assay for a lentiviral gene therapy vector, measuring percent metabolite reduction in transduced patient\-derived cells\. The method met precision, assay performance, and system suitability criteria across two analysts and two days under a pre\-approved cGMP protocol\.\.\. - [Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry](https://www.avancebio.com/compliance-policy-regarding-blood-and-blood-component-donation-suitability-donor-eligibility-and-source-plasma-quarantine-hold-requirements-guidance-for-industry-2/): This guidance addresses certain requirements that apply to blood establishments that collect blood and blood components, including Source Plasma\. Specifically, the guidance explains the conditions under which FDA does not intend to take regulatory action for a blood establishment’s failure to comply with certain requirements in Title 21 of the\.\.\. ## Optional - [Sitemap index](https://www.avancebio.com/sitemap_index.xml)